Tamoxifen News and Research

RSS

Tamoxifen is a drug used to treat certain types of breast cancer in women and men. It is also used to prevent breast cancer in women who have had ductal carcinoma in situ (abnormal cells in the ducts of the breast) and in women who are at a high risk of developing breast cancer. Tamoxifen is also being studied in the treatment of other types of cancer. It blocks the effects of the hormone estrogen in the breast. Tamoxifen is a type of antiestrogen. Also called tamoxifen citrate.

Tamoxifen reduces long-term risk of cancer

According to a new study released this week, women at high risk for breast cancer who take the well-known drug Tamoxifen, can reduce their long-term risk of developing the disease.

16 Nov 2005

Ospemifine may also help to prevent breast cancer

A tamoxifen-like drug developed by UC Davis and Finnish researchers, now in clinical testing as a treatment for vaginal atrophy, may also help to prevent breast cancer, two preliminary studies suggest.

3 Nov 2005

Substance found in evening primrose oil inhibits breast cancer gene

Gamma-linolenic acid (GLA), a substance in evening primrose oil and several other plant oils used in herbal medicine, inhibits action of Her-2/neu, a cancer gene that is responsible for almost 30 percent of all breast cancers, Northwestern University researchers report.

3 Nov 2005

First study to confirm the benefit of anti-angiogenic therapy in patients with breast cancer

Results from the first and only interim analysis of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after adjuvant chemotherapy, have shown that Herceptin affords a significant survival advantage.

1 Nov 2005

Mammograms a big factor in the fight against breast cancer

A new study has come down solidly on the side of routine screening mammograms as a preventative measure in the fight against cancer.

27 Oct 2005

Early detection and improved treatment have contributed almost equally to the substantial decrease in breast cancer

Early detection through screening mammography and improved adjuvant treatment have contributed almost equally to the substantial decrease in breast cancer death rates over the past 10 to 15 years, researchers conclude in an unprecedented effort to parse out the factors that have led to the decline.

27 Oct 2005

Survival benefits of longer-term tamoxifen use may take years to appear

The survival benefits of longer-term therapy using tamoxifen may take at least nine years to develop, according to a new study published in the December 1, 2005 issue of Cancer, a peer-reviewed journal of the American Cancer Society.

24 Oct 2005

Women on breast cancer treatment opt for injections to curb hot flashes

Apparently, given a choice, many breast cancer patients using hormone therapies such as Tamoxifen to cut the risk of recurrence, would opt for pills rather than injections.

24 Oct 2005

Breast cancer drug Herceptin a 'stunner'

According to the New England Journal of Medicine (NEJM) the first trials of the breast cancer drug, Herceptin, tested on women with early stage disease are "simply stunning".

20 Oct 2005

Distress caused by hot flushes seriously under-played

A study by UK researchers of over 200 breast cancer patients receiving hormone treatments such as tamoxifen has found that nearly two-thirds would prefer to take a tablet daily and around a quarter would prefer a monthly injection, given that both treatments would be equally effective and have similar side-effects.

19 Oct 2005

Majority of women with breast cancer do not need chemotherapy

Researchers are now saying that chemotherapy with drugs called aromatase inhibitors is unnecessary after lumpectomy, radiation and 5 years of Tamoxifen, for the vast majority of women with breast cancer.

19 Oct 2005

Largest known series of data examining the sequencing of tamoxifen and radiation

Fox Chase Cancer Center researchers say the sequence of tamoxifen and radiation following lumpectomy for early-stage breast cancer patients does not affect disease control, survival or complication rates, but administering tamoxifen concurrently with radiation has negative cosmetic results.

16 Oct 2005

Americans' risk of dying from cancer continues to decline

The nation's leading cancer organizations report that Americans' risk of dying from cancer continues to decline and that the rate of new cancers is holding steady. The "Annual Report to the Nation on the Status of Cancer, 1975-2002," published in the Oct. 5, 2005, issue of the Journal of the National Cancer Institute, shows observed cancer death rates from all cancers combined dropped 1.1 percent per year from 1993 to 2002.

4 Oct 2005

Researchers look at pharmacogenomics

When patients receive chemotherapy, 15 percent will have severe side effects while 85 percent will not - even though they're given the same relative dose.

28 Sep 2005

Questionnaire helps identify women who have inherited genetic mutations that increase their risk for breast or ovarian cancer

A simplified way for patients to report and update their family medical histories could help identify women who have inherited genetic mutations that increase their risk for breast or ovarian cancer.

26 Sep 2005

First true animal model for psoriasis

Scientists at the Research Institute of Molecular Pathology in Vienna have developed the first true animal model for psoriasis and have been able to address the initial steps and possible causes of the disease.

20 Sep 2005

Why do estrogen-dependent breast-cancer cells grow and spread rapidly?

Researchers at the University of Illinois at Urbana-Champaign say it may be because estrogen virtually eliminates levels of a vitally important regulatory protein.

10 Sep 2005

Letrozole following tamoxifen may benefit women with breast cancer

Switching to the drug letrozole following 5 years of treatment with tamoxifen reduces the risk of hormone-dependent breast cancer recurrence, but not overall survival, among postmenopausal women, according to a new study in the September 7 issue of the Journal of the National Cancer Institute.

7 Sep 2005

Testing for specific breast cancer genes unadvisable if no family history of disease exists

According to the Preventive Services Task Force in the U.S., routine testing for mutations in the BRCA1 and BRCA2 genes, which have been linked to breast and ovarian cancer, are not advised unless women have a family history of the disease.

7 Sep 2005

Recent evidence suggests caution in prescribing hormone therapy for breast cancer

One of the most effective new treatments for breast cancer is a hormone therapy. Aromatase inhibitors work by powerfully blocking the conversion of androgen precursors into estrogens, which lowers estradiol levels in the bloodstream and estrogen levels in peripheral tissues.

4 Sep 2005